Leiden Dworak - 14 Aug 2025 Form 3 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role: Principal Accounting Officer
Signature: /s/ Zoran Zdraveski, Attorney-in-Fact
Issuer symbol: TCRX
Transactions as of: 14 Aug 2025
Net transactions value: $0
Form type: 3
Filing time: 22 Aug 2025, 16:10:04 UTC
Previous filing: 11 Feb 2025
Next filing: 22 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Dworak Leiden	Principal Accounting Officer	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM	/s/ Zoran Zdraveski, Attorney-in-Fact	22 Aug 2025	0001986012

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TCRX	Stock Option (Right to Buy)							14 Aug 2025	Voting Common Stock	37,500	$2.90	Direct	F1
holding	TCRX	Stock Option (Right to Buy)							14 Aug 2025	Voting Common Stock	23,750	$1.81	Direct	F2
holding	TCRX	Stock Option (Right to Buy)							14 Aug 2025	Voting Common Stock	163,800	$2.49	Direct	F3
holding	TCRX	Stock Option (Right to Buy)							14 Aug 2025	Voting Common Stock	25,000	$2.23	Direct	F4
holding	TCRX	Stock Option (Right to Buy)							14 Aug 2025	Voting Common Stock	46,875	$6.00	Direct	F5
holding	TCRX	Stock Option (Right to Buy)							14 Aug 2025	Voting Common Stock	70,000	$3.06	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of April 4, 2022, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.
F2	The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of February 2, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.
F3	96,300 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 67,500 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023.
F4	The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of July 21, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.
F5	The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 12, 2024, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.
F6	The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 3, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney